WALTHAM, Mass., Oct. 03, 2016 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the appointment of Ross Pettit as Senior Vice President, Global Development Operations. Mr. Pettit will be responsible for leading global clinical operations including operational project management, outsourcing, data management, and clinical drug supply.
“We are pleased to welcome Ross to our senior leadership team,” said John V. Oyler, Founder, Chief Executive Officer, and Chairman of BeiGene. “Ross has extensive experience in drug development operations, built over a long career. We believe Ross’s expertise will be valuable in helping to ensure the smooth execution of our development plans as our pipeline advances into late-stage development.”
“I’m excited to join BeiGene and lead its global development operations. With four proprietary assets in the clinic and a global approach to drug development, this is an opportune time to join the company,” commented Mr. Pettit.
Mr. Pettit has more than 30 years of experience in the biopharmaceutical industry, most recently at Infinity Pharmaceuticals where he was Senior Vice President of Development Operations and responsible for the execution of the company’s clinical programs including late-stage studies in B-cell malignancies. Before joining Infinity Pharmaceuticals, Mr. Pettit held senior roles in Clinical Operations at AMAG Pharmaceuticals, ARIAD Pharmaceuticals, and Coley Pharmaceutical Group. Mr. Pettit has also held roles in Regulatory Affairs, Program Management, Medical Affairs, and Clinical Research during his long-standing career. He earned his undergraduate degree in Applied Sciences from the University of Kingston, London, U.K. and holds a Master of Business Administration in Healthcare Management from the University of Phoenix.
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 250 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s advancement of, and anticipated development and regulatory milestones and plans related to, BeiGene’s drug candidates and clinical trials. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; BeiGene’s ability to achieve market acceptance in the medical community necessary for commercial success; BeiGene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene’s reliance on third parties to conduct preclinical studies and clinical trials; BeiGene’s limited operating history and BeiGene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in the BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
CONTACT: Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 firstname.lastname@example.org email@example.com